B6-huAPRIL (huTNFSF13) Mouse
Product Name
B6-huAPRIL (huTNFSF13) Mouse
Product ID
C001852
Strain Name
C57BL/6NCya-Tnfsf13tm1(hTNFSF13)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “B6-huAPRIL (huTNFSF13) Mouse (Catalog C001852) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
TNFSF13
Gene Alias
APRIL, CD256, TALL2, ZTNF2, TALL-2, TNLG7B, TRDL-1, UNQ383/PRO715
NCBI ID
Chromosome
Chr 17 (Human)
MGI ID
Datasheet
Strain Description
The TNFSF13 gene, also known as APRIL (a proliferation-inducing ligand), encodes a critical member of the tumor necrosis factor (TNF) superfamily. Its expression is detected in various cell types within the immune and stromal compartments, including monocytes, macrophages, dendritic cells, and bone marrow precursors [1]. The encoded cytokine functions by binding to specific receptors, namely TNFRSF17/BCMA and TNFRSF13B/TACI, thereby regulating key aspects of B cell and plasma cell biology, including their development and long-term survival. TNFSF13 is instrumental in the adaptive immune response, facilitating antibody class switching and providing essential survival cues to antibody-secreting cells [2]. Dysregulated TNFSF13 expression has been etiologically linked to various pathologies. Aberrant TNFSF13 signaling contributes to the pathogenesis of multiple myeloma and chronic lymphocytic leukemia (CLL) by promoting the proliferation and survival of malignant cells [3]. Furthermore, its dysregulation is also implicated in the progression of several autoimmune disorders, such as rheumatoid arthritis (RA), IgA nephropathy, and systemic lupus erythematosus (SLE) [4].
The B6-huAPRIL (huTNFSF13) mouse is a humanized model constructed via gene-editing technology. The sequence from the ATG start codon to the TGA stop codon of mouse Tnfsf13 is replaced with the sequence from the ATG start codon to the TGA stop codon of human TNFSF13. B6-huAPRIL (huTNFSF13) mice can be used for research into the pathogenesis of autoimmune disorders like rheumatoid arthritis (RA), IgA nephropathy, and systemic lupus erythematosus (SLE), as well as some cancers, and for the development of TNFSF13-targeted drugs.
Reference
Chen R, Wang X, Dai Z, Wang Z, Wu W, Hu Z, Zhang X, Liu Z, Zhang H, Cheng Q. TNFSF13 Is a Novel Onco-Inflammatory Marker and Correlates With Immune Infiltration in Gliomas. Front Immunol. 2021 Oct 12;12:713757.
Poznyak AV, Gerasimova EV, Orekhov NA, Karimova AE, Vergun MA, Lapshina KO, Sukhorukov VN, Orekhov AN. Exploring the role of APRIL in autoimmunity: implications for therapeutic targeting in systemic lupus erythematosus, rheumatoid arthritis, and Sjögren's syndrome. Front Immunol. 2025 Aug 1;16:1523392.
Ullah MA, Mackay F. The BAFF-APRIL System in Cancer. Cancers (Basel). 2023 Mar 16;15(6):1791.
Muto M, Suzuki H, Suzuki Y. New Insights and Future Perspectives of APRIL in IgA Nephropathy. Int J Mol Sci. 2024 Sep 26;25(19):10340.
Strain Strategy
The sequences from the ATG start codon to the TGA stop codon of the endogenous mouse Tnfsf13 gene were replaced with the sequences from the ATG start codon to the TGA stop codon of the human TNFSF13 gene. The Neo cassette was inserted downstream of the TGA stop codon. The function of the mouse Tnfsfm13 and Tnfsf13os genes will be affected.
Figure 1. Gene editing strategy of B6-huAPRIL (huTNFSF13) mice.
Application Area
TNFSF13-targeted drug screening, development, and evaluation;
Research on the pathological mechanisms and therapeutic approaches of certain cancers;
Research on the pathological mechanisms and therapeutic approaches of autoimmune disorders, such as rheumatoid arthritis (RA), IgA nephropathy, and systemic lupus erythematosus (SLE).
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
